scholarly journals Investigation of Atrial Vulnerability by Analysis of the Sinus Node EG From Atrial Fibrillation Models Using a Phase Synchronization Method

2012 ◽  
Vol 59 (9) ◽  
pp. 2668-2676 ◽  
Author(s):  
Ying Chen ◽  
Zhong Wu ◽  
Cuiwei Yang ◽  
Jun Shao ◽  
K. K. L. Wong ◽  
...  
2010 ◽  
Vol 34 (2) ◽  
pp. 163-170 ◽  
Author(s):  
GANG CHEN ◽  
JIAN ZENG DONG ◽  
XING PENG LIU ◽  
XIN YONG ZHANG ◽  
DE YONG LONG ◽  
...  

2011 ◽  
Vol 141 (6) ◽  
pp. 1455-1460 ◽  
Author(s):  
Yoshiharu Soga ◽  
Hitoshi Okabayashi ◽  
Yoshio Arai ◽  
Takuya Nomoto ◽  
Jota Nakano ◽  
...  

1968 ◽  
Vol 96 (4) ◽  
pp. 333-339 ◽  
Author(s):  
Koichi Nakayama ◽  
Yasuyuki Suzuki ◽  
Koroku Hashimoto

2017 ◽  
Vol 44 (2) ◽  
pp. 107-114 ◽  
Author(s):  
Zhengyu Bao ◽  
Hongwu Chen ◽  
Bing Yang ◽  
Michael Shehata ◽  
Weizhu Ju ◽  
...  

The efficacy of pulmonary vein antral isolation for patients with prolonged sinus pauses (PSP) on termination of atrial fibrillation has been reported. We studied the right atrial (RA) electrophysiologic and electroanatomic characteristics in such patients. Forty patients underwent electroanatomic mapping of the RA: 13 had PSP (group A), 13 had no PSP (group B), and 14 had paroxysmal supraventricular tachycardia (control group C). Group A had longer P-wave durations in lead II than did groups B and C (115.5 ± 15.4 vs 99.5 ± 10.9 vs 96.5 ± 10.4 ms; P=0.001), and RA activation times (106.8 ± 13.8 vs 99 ± 8.7 vs 94.5 ± 9.1 s; P=0.02). Group A's PP intervals were longer during adenosine triphosphate testing before ablation (4.6 ± 2.3 vs 1.7 ± 0.6 vs 1.5 ± 1 s; P <0.001) and after ablation (4.7 ± 2.5 vs 2.2 ± 1.4 vs 1.6 ± 0.8 s; P <0.001), and group A had more complex electrograms (11.4% ± 5.4% vs 9.3% ± 1.6% vs 5.8% ± 1.6%; P <0.001). Compared with group C, group A had significantly longer corrected sinus node recovery times at a 400-ms pacing cycle length after ablation, larger RA volumes (100.1 ± 23.1 vs 83 ± 22.1 mL; P=0.04), and lower conduction velocities in the high posterior (0.87 ± 0.13 vs 1.02 ± 0.21 mm/ms; P=0.02) and high lateral RA (0.89 ± 0.2 vs 1.1 ± 0.35 mm/ms; P=0.04). We found that patients with PSP upon termination of atrial fibrillation have RA electrophysiologic and electroanatomic abnormalities that warrant post-ablation monitoring.


2021 ◽  
Vol 25 (3) ◽  
pp. 51
Author(s):  
A. S. Zalesov ◽  
A. V. Bogachev-Prokophiev ◽  
A. V. Afanasyev ◽  
R. M. Sharifulin ◽  
A. V. Sapegin ◽  
...  

<p><strong>Background.</strong> Hypertrophic cardiomyopathy is one of the most common types of cardiomyopathy. The appearance of atrial fibrillation in patients with hypertrophic obstructive cardiomyopathy is associated with significant clinical worsening. Outcomes of surgical ablation and septal myectomy in these patients are limited.<br /><strong>Aim.</strong> This retrospective study aimed to evaluate short-term outcomes of concomitant surgical ablation and septal myectomy in patients with obstructive hypertrophic cardiomyopathy and atrial fibrillation.<br /><strong>Methods.</strong> Fifty-five patients with hypertrophic obstructive cardiomyopathy and atrial fibrillation who underwent concomitant surgical ablation and septal myectomy between 2014 and 2019 were analysed. Patients with paroxysmal atrial fibrillation predominantly underwent left atrial ablation, and those with nonparoxysmal atrial fibrillation predominantly underwent the Maze IV procedure. Surgical ablation was performed using cryoablation alone (83.6%) or in combination with radiofrequency energy (16.4%).<br /><strong>Results.</strong> Hospital mortality was 1.8%. Incidence of major adverse events was 3.6%. Sinus node dysfunction and atrioventricular block occurred in 7.3% and 1.8% of patients, respectively. Bleeding requiring revision occurred in 2 (3.6%) patients. Forty-nine (89.1%) patients had stable sinus rhythm and five (9.1%) were on dual-chamber pacemaker stimulation at the time of discharge.<br /><strong>Conclusion.</strong> Concomitant septal myectomy and surgical ablation are feasible and safe in patients with hypertrophic obstructive cardiomyopathy and atrial fibrillation.</p><p>Received 5 April 2021. Revised 16 May 2021. Accepted 17 May 2021.</p><p><strong>Funding:</strong> The study did not have sponsorship.</p><p><strong>Conflict of interest:</strong> The authors declare no conflicts of interests.</p><p><strong>Contribution of the authors</strong><br />Conception and study design: A.S. Zalesov, A.V. Bogachev-Prokophiev<br />Data collection and analysis: A.S. Zalesov, S.A. Budagaev, A.V. Sapegin<br />Statistical analysis: A.S. Zalesov, A.V. Afanasyev, R.M. Sharifulin<br />Drafting the article: A.S. Zalesov<br />Critical revision of the article: A.V. Bogachev-Prokophiev, S.I. Zheleznev, I.I. Demin<br />Final approval of the version to be published: A.S. Zalesov, A.V. Bogachev-Prokophiev, A.V. Afanasyev, R.M. Sharifulin, A.V. Sapegin, S.A. Budagaev, S.I. Zheleznev, I.I. Demin</p>


Sign in / Sign up

Export Citation Format

Share Document